VIDEO: Revumenib ‘exciting’ for certain patients with relapsed/refractory AML

SAN DIEGO — In this video, Catherine Lai, MD, MPH, discusses the results from the Augment-101 phase 2 study presented at ASH Annual Meeting and Exposition.
The study assessed the safety and efficacy of revumenib (SNDX-5613, Syndax Pharmaceuticals) among patients with relapsed/refractory KMT2A rearranged acute myeloid leukemia.
“In general, this is a very challenging to treat population and historically has had very dismal outcomes,” Lai, an associate professor and physician leader of the Leukemia Clinical Research Unit at University of Pennsylvania’s Perelman Center for

Leave a Comment

Your email address will not be published. Required fields are marked *

Shopping Cart
This website uses cookies and asks your personal data to enhance your browsing experience.